NLS In a new job

Nykode Therapeutics has announced the proposed election of Dr. Barbara Krebs-Pohl as the new Chair of the Board, succeeding Susanne Stuffers, who has served as interim Chair since April 2025.

Gesynta Pharma has announced the formation of a Scientific Advisory Board (SAB) to provide strategic advice in the clinical development of vipoglanstat, a non-hormonal, non-opioid treatment for endometriosis that is currently in Phase 2 (the NOVA trial).

Danish diabetes‑tech company Hedia is implementing a leadership change.

Per Johansson succeeds founder Klavs Esbjerg, who transitions to strategic board role after 16 years of transformative leadership.

Jesper Hagberg brings over 25 years of experience as CIO, CDO and Transformation Leader, driving major transformation programs across global organizations.

Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy.